Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
164 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Inflammatory Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Inflammatory Pain - Pipeline Review, H2 2014', provides an overview of the Inflammatory Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Inflammatory Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Inflammatory Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Inflammatory Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Inflammatory Pain Overview 8 Therapeutics Development 9 Pipeline Products for Inflammatory Pain - Overview 9 Pipeline Products for Inflammatory Pain - Comparative Analysis 10 Inflammatory Pain - Therapeutics under Development by Companies 11 Inflammatory Pain - Therapeutics under Investigation by Universities/Institutes 15 Inflammatory Pain - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Inflammatory Pain - Products under Development by Companies 18 Inflammatory Pain - Products under Investigation by Universities/Institutes 21 Inflammatory Pain - Companies Involved in Therapeutics Development 22 Boehringer Ingelheim GmbH 22 Kyowa Hakko Kirin Co., Ltd. 23 Shionogi & Co., Ltd. 24 AstraZeneca PLC 25 MedImmune, LLC 26 Merck & Co., Inc. 27 Takeda Pharmaceutical Company Limited 28 Glenmark Pharmaceuticals Ltd. 29 Pfizer Inc. 30 Evotec AG 31 Anavex Life Sciences Corp. 32 Array BioPharma Inc. 33 Pluristem Therapeutics Inc. 34 BCN Peptides, S.A. 35 Upsher-Smith Laboratories, Inc. 36 Grunenthal GmbH 37 Integral Molecular, Inc. 38 AngioChem Inc. 39 Asahi Kasei Pharma Corp. 40 Hydra Biosciences, Inc. 41 NeurAxon, Inc. 42 Cara Therapeutics, Inc. 43 CLL Pharma 44 Dompe Farmaceutici S.p.A. 45 Lohocla Research Corporation 46 MAKScientific, LLC 47 RaQualia Pharma Inc. 48 Sunovion Pharmaceuticals Inc. 49 Adynxx, Inc. 50 Kareus Therapeutics, SA 51 AnaBios Corporation 52 Creabilis SA 53 Istituto Italiano di Tecnologia 54 Infirst Healthcare Limited 55 AbbVie Inc. 56 Epirus Biopharmaceuticals, Inc. 57 Inflammatory Pain - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Target 59 Assessment by Mechanism of Action 63 Assessment by Route of Administration 67 Assessment by Molecule Type 69 Drug Profiles 71 grapiprant - Drug Profile 71 Z-944 - Drug Profile 73 DD-04107 - Drug Profile 74 S-120083 - Drug Profile 75 SYN-1002 - Drug Profile 76 GBR-900 - Drug Profile 77 Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile 78 Small Molecule to Antagonize Bradykinin Receptor B1 for Pain - Drug Profile 79 OX-MPI - Drug Profile 80 Small Molecule to Inhibit nNOS/iNOS for Inflammatory Pain - Drug Profile 81 HC-030031 - Drug Profile 82 CR-845 - Drug Profile 83 Small Molecule to Antagonize TrkA for Inflammatory Pain - Drug Profile 85 ANAVEX-1079 - Drug Profile 86 ANG-2002 - Drug Profile 87 AMAP-102 - Drug Profile 88 CT-340 - Drug Profile 90 RQ-00000008 - Drug Profile 91 CR-701 - Drug Profile 92 Small molecules To Inhibit CDK9 for Central Nervous System and Immunology - Drug Profile 93 AK-106 - Drug Profile 94 Z-212 - Drug Profile 95 Stem Cell Therapy for Neuropathic and Inflammatory Pain - Drug Profile 96 conolidine - Drug Profile 97 AYX-3 - Drug Profile 98 Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis - Drug Profile 99 Biologic 2 for Central Nervous System - Drug Profile 100 Drugs to Inhibit SRC-ND2 Interaction for Neuropathic Pain and Inflammatory Pain - Drug Profile 101 Small Molecule Targeting Cannabinoid Receptor For Inflammatory Pain - Drug Profile 102 AR-786 - Drug Profile 103 AZ-1 - Drug Profile 104 AZ-2 - Drug Profile 105 Small Molecule to Inhibit FAAH for Pain - Drug Profile 106 Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 107 ZJ-43 - Drug Profile 108 Drug to Inhibit Glutaminase for Inflammatory Pain - Drug Profile 109 MK-8825 - Drug Profile 110 MAK-2124 - Drug Profile 111 A-836339 - Drug Profile 112 Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment - Drug Profile 113 ibuprofen - Drug Profile 114 Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders - Drug Profile 115 PNU-120596 - Drug Profile 116 AB-144 - Drug Profile 117 NET-END - Drug Profile 118 PF-3845 - Drug Profile 119 BIBN-4096BS - Drug Profile 120 Peptide to Block Calcium Channel for CNS Disorders - Drug Profile 121 Small Molecules to Inhibit TRPA1 and TRPV1 for CNS - Drug Profile 122 URB-937 - Drug Profile 124 BBI-11008 - Drug Profile 125 A-1048400 - Drug Profile 126 NH-34 - Drug Profile 127 K-685 - Drug Profile 128 ET-1 - Drug Profile 129 GRTTA-2210 - Drug Profile 130 RO-656570 - Drug Profile 131 FV-082 - Drug Profile 132 FV-137 - Drug Profile 133 Small Molecules to Antagonize Cav3.2 for Pain - Drug Profile 134 DF-2593A - Drug Profile 135 UNC-3230 - Drug Profile 136 Kindolor - Drug Profile 137 Nav 1.7 Blocker Program - Drug Profile 139 Nav1.8 Sodium Channel Blocker For Pain - Drug Profile 140 Biologic 1 for Central Nervous System - Drug Profile 141 Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile 142 Inflammatory Pain - Recent Pipeline Updates 143 Inflammatory Pain - Dormant Projects 151 Inflammatory Pain - Discontinued Products 152 Inflammatory Pain - Product Development Milestones 153 Featured News & Press Releases 153 Appendix 158 Methodology 158 Coverage 158 Secondary Research 158 Primary Research 158 Expert Panel Validation 158 Contact Us 159 Disclaimer 159
List of Tables Number of Products under Development for Inflammatory Pain, H2 2014 14 Number of Products under Development for Inflammatory Pain - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Development by Companies, H2 2014 (Contd..1) 24 Products under Development by Companies, H2 2014 (Contd..2) 25 Products under Investigation by Universities/Institutes, H2 2014 26 Inflammatory Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2014 27 Inflammatory Pain - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 28 Inflammatory Pain - Pipeline by Shionogi & Co., Ltd., H2 2014 29 Inflammatory Pain - Pipeline by AstraZeneca PLC, H2 2014 30 Inflammatory Pain - Pipeline by MedImmune, LLC, H2 2014 31 Inflammatory Pain - Pipeline by Merck & Co., Inc., H2 2014 32 Inflammatory Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 33 Inflammatory Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 34 Inflammatory Pain - Pipeline by Pfizer Inc., H2 2014 35 Inflammatory Pain - Pipeline by Evotec AG, H2 2014 36 Inflammatory Pain - Pipeline by Anavex Life Sciences Corp., H2 2014 37 Inflammatory Pain - Pipeline by Array BioPharma Inc., H2 2014 38 Inflammatory Pain - Pipeline by Pluristem Therapeutics Inc., H2 2014 39 Inflammatory Pain - Pipeline by BCN Peptides, S.A., H2 2014 40 Inflammatory Pain - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 41 Inflammatory Pain - Pipeline by Grunenthal GmbH, H2 2014 42 Inflammatory Pain - Pipeline by Integral Molecular, Inc., H2 2014 43 Inflammatory Pain - Pipeline by AngioChem Inc., H2 2014 44 Inflammatory Pain - Pipeline by Asahi Kasei Pharma Corp., H2 2014 45 Inflammatory Pain - Pipeline by Hydra Biosciences, Inc., H2 2014 46 Inflammatory Pain - Pipeline by NeurAxon, Inc., H2 2014 47 Inflammatory Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 48 Inflammatory Pain - Pipeline by CLL Pharma, H2 2014 49 Inflammatory Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 50 Inflammatory Pain - Pipeline by Lohocla Research Corporation, H2 2014 51 Inflammatory Pain - Pipeline by MAKScientific, LLC, H2 2014 52 Inflammatory Pain - Pipeline by RaQualia Pharma Inc., H2 2014 53 Inflammatory Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 54 Inflammatory Pain - Pipeline by Adynxx, Inc., H2 2014 55 Inflammatory Pain - Pipeline by Kareus Therapeutics, SA, H2 2014 56 Inflammatory Pain - Pipeline by AnaBios Corporation, H2 2014 57 Inflammatory Pain - Pipeline by Creabilis SA, H2 2014 58 Inflammatory Pain - Pipeline by Istituto Italiano di Tecnologia, H2 2014 59 Inflammatory Pain - Pipeline by Infirst Healthcare Limited, H2 2014 60 Inflammatory Pain - Pipeline by AbbVie Inc., H2 2014 61 Inflammatory Pain - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 62 Assessment by Monotherapy Products, H2 2014 63 Number of Products by Stage and Target, H2 2014 66 Number of Products by Stage and Mechanism of Action, H2 2014 70 Number of Products by Stage and Route of Administration, H2 2014 73 Number of Products by Stage and Molecule Type, H2 2014 75 Inflammatory Pain Therapeutics - Recent Pipeline Updates, H2 2014 148 Inflammatory Pain - Dormant Projects, H2 2014 156 Inflammatory Pain - Discontinued Products, H2 2014 157
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.